本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Nov. 26, 2024 /PRNewswire/ -- In recent years, the integration of artificial intelligence (AI) and robotics into the medical field has revolutionized healthcare technologies. The focus now is on bridging the gap between cutting-edge technologies and clinical applications to enhance diagnostic capabilities and improve overall healthcare efficiency. On November 22-23, the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science and Innovation, Chinese Academy of Sciences hosted the Second Hong Kong Clinical-driven Robotics and Embodied AI TEchnology Symposium (CREATE Symposium) at the Charles K. Kao Auditorium, Hong Kong Science Park. This two-day symposium brought together a distinguished lineup of international experts, clinicians, and medical device innovators to foster cross-disciplinary dialogues spanning academic research, industry development, and clinical applications. Participants exchanged insights on the latest breakthroughs and future trends in healthcare technologies, propelling the innovative application of AI and robotics in medical practice. Following the success of the first day, the second day of the CREATE Symposium featured insightful discussions by more than 10 experts, focusing on the applications of AI in medical device innovation and clinical practices. In his welcome speech, Professor Zhen Lei, IEEE/IAPR Fellow and Professor of CAIR emphasized CAIR's mission: "CAIR is committed to becoming an international R&D hub for scientific and technological innovation, advancing AI research and intelligent design, and fostering new momentum for both mainland and international communities. By bringing together global talent and technology, we aim to establish Hong Kong as an international hub for innovation in intelligent technology." Mr. Changlin Gao, General Manager of Beijing-Hong Kong Exchange of Personnel Centre, representing one of the supporting organizations, highlighted the forum's role in creating a high-level platform for collaboration: "This forum has established a platform for the international academia, industry, and medical community to jointly explore the cutting-edge applications and future directions of AI technology in healthcare. From Exploration to Practice: AI Empowering the Future of Healthcare Professor Dinggang Shen, Founding Dean of the School of Biomedical Engineering at the ShanghaiTech University and Co-CEO of United Imaging Intelligence, highlighted how AI technology is advancing the standardization and intelligent development of medical diagnoses and treatments. By integrating multimodal data, including imaging, pathology, and genomics, AI is improving medical efficiency, optimizing resource allocation, and enhancing patient outcomes. He also shared his team's innovative work in areas such as image enhancement, low-dose imaging, and comprehensive cancer diagnosis. In the field of surgery, embodied AI technology is gradually being integrated into minimally invasive procedures and surgical robots, providing surgeons with high-precision, low-risk assistance. Professor Hongbin Liu, Director of CAIR, stated that the goal of AI is to empower rather than replace humans, enabling doctors to become "super doctors". He envisioned the future operating rooms become fully intelligent spaces where humans and robots collaborate seamlessly, improving surgical outcomes through advanced interaction. . Professor Shaohua Zhou, Executive Dean of the School of Biomedical Engineering at the University of Science and Technology of China, emphasized the growing importance of general and foundational models in medical imaging AI. These models address challenges related to data scarcity and task complexity through a "train-once, multi-task" approach. He highlighted the integration of multimodal data and the combination of generative and discriminative models to develop reliable and interpretable intelligent systems capable of supporting clinical applications and improving patient health predictions. Some other distinguished experts and scholars shared their latest research progress and practical applications: Dr. Yongjian Chen, Deputy General Manager of Qingdao Hisense Medical Equipment Co., Ltd.; Dr. Qi Dou, Assistant Professor at Department of Computer Science and Engineering and T Stone Robotics Institute, The Chinese University of Hong Kong; Professor Zhong Wu, Director of Administration, Chief Physician at Cardiovascular Surgery, West China Hospital of Sichuan University; Dr. Kevin Ka-ho Kam, Director of Ambulatory Cardiology Services and Associate Consultant of Medicine & Therapeutics, Prince of Wales Hospital; Professor Lei Du, Chief Physician and Professor at the Department of Anesthesia, West China Hospital, Sichuan University; Dr. Huai Liao, Chief Physician at Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University; Dr. Shifang Li, Chief Physician, Neurosurgery, Affiliated Hospital of Qingdao University; Dr. Hua Wang, CTO of Magspin Instrument Co., Ltd. In the afternoon, the speakers visited the CAIR exhibition hall to explore CAIR's groundbreaking research achievements. Highlights included: CARES Copilot 2.0, Embodied Intelligent Ultrasound Robot, Augmented Reality Navigation Systems, Medical Imaging Enhancements Techniques, Real-time Surgical Digital Twin System, and Flexible Minimally Invasive Neurosurgery Robot. The visit sparked in-depth discussions on addressing clinical challenges and market commercialization. Later, a closed-door seminar focused on the clinical applications of AI and robotics in cardiothoracic surgery and intensive care. Earlier, around 40 young scholars from Hong Kong had visited the CAIR exhibition hall. They participated in a lunch discussion with project researchers, expressing strong interest in CAIR's research achievements and team culture. Many expressed their aspirations to join CAIR in the future. The successful conclusion of the "Hong Kong CREATE Symposium" not only highlights its pivotal role in advancing academic exchange and collaboration in the field of embodied intelligent medical technology, but also provides a cross-disciplinary and international platform for innovative dialogue among global experts and scholars. By uniting industry leaders, showcasing groundbreaking research, and delving into emerging trends, the forum serves as a catalyst for the continued evolution and practical application of embodied intelligent medical technology. Looking ahead, as these technologies continue to evolve and expand, their transformative potential in the healthcare sector will be further unlocked. This progress will not only drive innovation but also strengthen efforts toward the sustainable development of human society, offering new insights and solutions to global healthcare challenges. About CAIR Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences is the first national-level R&D institution in Hong Kong approved by the central government. It is also directly affiliated with the Chinese Academy of Sciences. The Centre for Artificial Intelligence and Robotics (CAIR) is one of the two innovation centers under its umbrella. CAIR focuses on research in areas such as multimodal AI surgical models, embodied AI medical robots, and the fundamental theories of AI. The goal is to build Hong Kong into an artificial intelligence hub with national support, attract international high-end talents, and establish an international innovation hub for the applications of artificial intelligence and robotics in medical technology and life sciences. For more information, please visit CAIR's WeChat public account or the Center's official website: https://www.cair-cas.org.hk
New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysis Accelerating global expansion with cutting-edge technology targeting MS, a prevalent condition in North America and Europe. SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced on the 25th that its brain MRI analysis software "Neurophet AQUA", has obtained 510(k) clearance from U.S. Food and Drug Administration (FDA) for its newly integrated multiple sclerosis (MS) analysis functionality. Neurophet AQUA FDA 510(k) Clearance The initial clearance, secured in May last year, authorized brain atrophy analysis using T1-weighted images derived from MRI scans, specifically targeting neurodegeneration conditions. The latest clearance extends the software's capabilities, incorporating advanced analysis of MS and white matter hyperintensities (WMH) using T2-FLAIR images. Neurophet AQUA analyzes MRI (magnetic resonance images) with AI technology to analyze brain atrophy and WMH observed in neurodegenerative diseases such as Alzheimer's disease. It provides rapid segmentation and analysis of brain images across all demographics, delivering results within just five minutes. The software's MS analysis technology quantifies lesions and structural changes, enabling precise measurement of lesion count, volume, and progression. Notably, it delivers robust segmentation across both 2D and 3D imaging methods of T2-FLAIR MRI at 1.5T and 3.0T, while also enabling volumetric analysis of brain regions without requiring 3D T1 imaging. MS is a demyelinating autoimmune disease of the central nervous system, affecting the brain, spinal cord, and optic nerves. Characterized by inflammatory and neurodegenerative damage, the condition predominantly impacts individuals aged 20 to 40, with a higher prevalence among women. MS is most common among Caucasians in North America and Europe, while its occurrence is relatively lower among Asian and African Americans. MRI is the gold standard for diagnosing MS, often supplemented with blood tests and cerebrospinal fluid analysis. MS has a high likelihood of recurrence, requiring continuous monitoring of prognosis through regular MRI scans. "MS is a neurological disorder that heavily relies on MRI for both diagnosis and disease monitoring, and the McDonald criteria, the diagnostic criteria for MS, specifically includes MRI confirmation of lesions disseminated in space and time," said Jake Junkil Been, Co-CEO of Neurophet. "Neurophet AQUA's advanced MS analysis technology significantly enhances efficiency and convenience for healthcare professionals, making it an indispensable tool in both diagnostic and prognostic stages." He added, "With MS being highly prevalent among Caucasians in North America and Europe, this FDA clearance marks a pivotal step in strengthening our foothold in the global market. We aim to leverage this milestone to expand our presence across the U.S., Europe, and beyond." About NeurophetNeurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", brain PET image analysis (PET tracer deposition) software "Neurophet SCALE PET", brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB". Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov. 23, 2024 /PRNewswire/ -- JCF Technology is a startup that independently developed 'MecKare', a radar sensor that measures biological signals in a non-contact manner, and provides a platform service that automatically connects users and guardians in two-way emergency situations through an artificial intelligence analysis system. Since its establishment in 2016, it has developed a highly accurate non-contact multi-biological radar sensor through many years of technology accumulation, and succeeded in commercializing the product for the first time in 2021. MecKare uses microwave radar and micro-Doppler signal processing technology to measure the user's heart rate, respiratory rate, and skin temperature within 16.4 ft in real time. The sensor can measure human body movement patterns using precise and highly responsive thermal infrared rays and can detect falls through pattern analysis based on changes in human movement. In particular, the movement and change of thermal infrared rays within the measurement range are detected in real time, and the trend of biomarkers that appear as advance signs before a person falls can be checked through differential motion detection that measures the user's movement pattern. It provides an alarm in advance by predicting before a person falls, enabling accuracy and quick response to accidents. As a result, it is possible to prevent safety accidents in the elderly by detecting emergency situations such as lonely death, cardiac arrest, breathing difficulties, and falls. Additionally, unlike other existing wearable devices such as smart watches or bands, MecKare does not need to be worn or attached to the body, so it can be used remotely via Wi-Fi without causing stress to the user. https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image02.png MecKare can be installed in the bedroom, bathroom, living room, or entrance of a home or facilities(Assisted Living, Nursing Home, etc) to provide 24-hour monitoring without a camera and detect abnormal signs in advance using a biometric information analysis algorithm and deliver them to the guardian. MecKare's radar biometric sensor is recognized in the global market for its technology as a device that obtains precisely customized biometric information while overcoming spatial constraints and without risk of privacy infringement. MecKare is being supplied to senior care facilities in Australia, Germany, Poland, Saudi Arabia, and China. In 2025, MecKare plans to conduct verification of vital signs such as attendance, fall prevention, and asthma of elderly people living in hospitals or assisted living in conjunction with local PPOs/HMOs in the United States. In summary, MecKare is a system that reduces user inconvenience and enables management of multiple patients. By being able to provide personalized health data analysis results, it will serve as an opportunity to change the market paradigm towards preventive smart care. We expect MecKare's A.I to play a role as an innovator that complements, rather than replaces, humans in care settings.
BEIJING, CHINA - Media OutReach Newswire - 22 November 2024 - The 2024 Beijing Changping Forum on Life Science, themed "Explore Life for A Shared Future" was grandly kicked off on November 22. The forum aims to further create an innovative ecosystem that is open, international, and full of market dynamism. It will help build Beijing Zhongguancun Life Science Park into a cutting-edge "Life Science Valley", accelerate the development of a pharmaceutical and healthcare industry highland with global competitiveness, and promote the high-quality development of the pharmaceutical and healthcare industry in Beijing. 2024 Beijing Changping Forum on Life Science A rich offering of offline and online activities Building a life science forum with international standards and influence The forum adopts the "1+8+1+N" model and provides offline + online simultaneous livestreaming, so as to build a life science forum with international standards and influence. Specifically speaking, the "1" stands for holding an opening ceremony. Lei Ping, Deputy Director of the National Medical Products Administration; Sun Shuo, Deputy Mayor of Beijing, and leaders of the Ministry of Industry and Information Technology were invited to address the event. 500 people, including diplomatic envoys in China, Nobel Prize winners, well-known scientists at home and abroad, heads of scientific research institutions, representatives of international organizations and business associations, heads of pharmaceutical and healthcare enterprises, and investors attended the opening ceremony. Springer Nature Group released the 2024 Global Life Sciences Cluster Innovation Development Report for the first time and the Top 20 List of Scientists in Nature Index Bioscience and Health Science, and the China Association of Medical Equipment announced the establishment of the Medical Equipment and Surgical Skills Training Center, which is the first intelligent surgical skills training center project in China in collaboration with the Amsterdam Medical Skills Center of the Netherlands. Besides, the International Medical Equipment City, a high-end medical equipment industrial cluster especially built by Changping District, was officially inaugurated. 2024 Beijing Changping Forum on Life Science The number "8" refers to holding eight parallel forums. The Forum on Innovation and Development of Advanced Medical Equipment, International Medicine R&D Forum and Forum on Innovation and Development of Synthetic Biological Manufacturing Technology took place based on cutting-edge fields in pharmaceuticals and healthcare sector; the Changping Forum on Innovation of Financial Investment in pharmaceutical and healthcare and Medical Equipment Intellectual Property Protection Forum was held based on the idea of technology serving the industry ecosystem; the Forum on Global Expansion of Products, the China-Russia Pharmaceutical Talent Development and Market Access Seminar, and the Chinese Medical Equipment Internationalization Development Seminar was held to promote international cooperation in healthcare. The second "1" means holding an exhibition display. Under the theme "Focusing on Cutting-Edge Technology to Lead Innovative Development," the forum will invite a wide range of pharmaceutical and healthcare companies. It also featured dedicated zones for frontier technologies, beauty and health innovations, and major medical equipment, providing a comprehensive display of the achievements of "Life Science Valley" and the latest advancements in life sciences. "N" means a series of supporting activities. Some related activities held by pharmaceutical and healthcare industry associations and enterprises were included in the series of activities of the forum to strengthen the momentum of the activities and continue to amplify influence. By regularly holding a series of forums such as the 2024 Clinical Biobank Innovation and Development Forum and the 2024 pharmaceutical and healthcare Industry Innovation and Development Forum, the forum continuously optimizes the innovation ecology, upgrades the development level, and builds a "new benchmark" for world-leading science and technology parks. Theme release, inaugural ceremony, and project signing ceremony Building a platform for cooperation, exchange, and common development At the opening ceremony, the 2024 Global Life Sciences Cluster Innovation Development Index Report, the Top 20 List of Scientists in Nature Index Bioscience and Health Science, and Project Plan of the Medical Equipment and Surgical Skills Training Center were released, and the International Medical Equipment City was also inaugurated. International Medical Equipment City is a specialized and complex industrial park focusing on high-end medical equipment, precision medicine, biotechnology, and other directions under the guidance and support of the National Medical Products Administration and the Beijing Municipal Medical Products Administration. The total construction area of the project is about 1.2 million square meters. About 430,000 square meters in the eastern district has been put into operation, and the construction of the western district is under progress. The park focuses on high-end medical equipments, high-value medical consumables, and efficient diagnostics, while closely following the trends of digitalization, intelligence, and personalization. It emphasizes clinical demonstration applications as a driving force, integrates the value realization of beauty and health management, and meets the full-cycle development needs of leading enterprises, including technology research, product development, result transformation, validation and iteration, and application implementation, so as to build an influential high-end medical equipment industrial cluster. Currently, the east district of International Medical Equipment City has attracted many high-end and sophisticated medical equipment enterprises such as Imeik, Balance Medical, Pins Medical, TowardPi Medical, Wellgrow Medical, TH Medical, New Cloud Medical, etc., covering medical equipment products in subdivided fields such as brain intelligence, implant intervention equipment, high-end diagnosis and treatment equipment, biomedical materials, cosmetic medicine equipment, and in vitro diagnosis, forming a "Changping Model" for the development of the medical equipment industry, characterized by its demonstrative, benchmark, and flagship qualities. At this year's forum, Changping District introduced a number of major industrial projects around the R&D layout of pharmaceutical companies and the transformation of original achievements. Twelve major industrial projects have been signed, including minimally invasive medical natural channel — bronchoscopy surgery robot, ROBO Medical surgery robot industrialization, Beijing Junming Medical health diagnosis industrial base, Donghuayuan innovative pharmacy automation industrial base, Qi Biodesign science headquarters, GenAns Tech China headquarters, etc. These enterprises include listed companies, national high-tech and industry-leading enterprises. It covers three tracks of cutting-edge technology, medical equipment, and synthetic biology, which are the focus of the pharmaceutical and healthcare industry in Changping, reflecting the innovation and industrial elements of headquarters R&D, incubation and cultivation, achievement transformation, and tech innovation finance in the field of life sciences. From the perspective of the industrial sectors, the signed projects feature major projects on key tracks with cutting-edge technology and high growth, mainly including Qi Biodesign science headquarters and GenAns Tech China headquarters. There are also major projects on the well-established sectors like medical equipment, including ROBO Medical surgery robot industrialization, the minimally invasive medical natural channel — bronchoscopy surgery robot, etc. There are also major projects in the new synthetic biology track, including Weiyuan Synthesis biotechnology R&D and the production line expansion project of Cargill Asia Pacific. From the perspective of project types, the signed projects include both global well-known enterprise projects and high-tech enterprise projects in China, including WellGene Biotech China headquarters, Beijing Junming Medical health diagnosis industry base, and other projects. Among these projects, there are both space settlement projects and service platform construction projects, mainly including cooperation signing ceremonies of Life Science Valley international precision medicine industrial park settlement, International Medical Equipment City settlement, Zhongguancun Life Science Park digital intelligent R&D conditions guarantee service platform construction, etc. Three features and numerous highlights Building a grand event for win-win international cooperation The forum aims to serve the national strategy, enhance Beijing's development, and promote high-quality growth in the pharmaceutical and healthcare industries. It will also contribute to building the "Life Science Valley" brand of Changping, optimize the innovation ecosystem in the sector, and create a first-rate business environment. The three main characteristics of the forum include: First, the forum offers rich content and fosters integration. With the main forum and over 20 supporting events, it will, for the first time, include four main sections: an academic conference, an industry forum, project exchange sessions, and cultural activities. These will focus on key areas such as cutting-edge technologies, medical devices, beauty and health, and synthetic biology manufacturing. Additionally, the forum will cover crucial aspects like pharmaceutical R&D, financial investment, and product expansion abroad, further promoting the integrated development of government, industry, academia, research, medical, finance, and intermediary sectors. Second, the forum focuses on cutting-edge advancements and drives innovation. By targeting disruptive technologies in life sciences, it will explore trends in life science innovation through various formats, including industry forums, innovation project competitions and roadshows, and product exhibitions, so as to secure a leading position in emerging fields, foster new productive forces, and establish a benchmark for innovation and future development in life sciences. Third, the forum aligns with international standards to foster open collaboration. Parallel forums will address topics such as international partnerships, product expansion overseas, and the global growth of pharmaceutical companies. For the first time, an overseas sub-forum will be established to facilitate cross-border communication, sign international cooperation agreements in the pharmaceutical and health industry, and support the global expansion of companies in this sector. Hashtag: #BeijingChangpingForumonLifeScienceThe issuer is solely responsible for the content of this announcement.
The first uMI Panvivo in the world lands at the growing Pueblo Medical Imaging in Nevada. HOUSTON, Nov. 22, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has installed the world's first uMI Panvivo PET/CT at Pueblo Medical Imaging in Nevada, USA. The uMI Panvivo is a powerful advanced platform that expands upon United Imaging's fully digital PET/CT portfolio with industry leading NEMA spatial resolution of 2.9 mm*. With an effective sensitivity of 181 counts per second per kilobecquerel (cps/kBq) and digital AI-driven 3D camera technology the uMI Panvivo delivers precision and care for all, while fostering success for all. The uMI Panvivo was recently introduced at the annual meeting for EANM (The European Association of Nuclear Medicine) in Hamburg. It will also be one of the products launched at RNSA (Radiologic Society of North America), at 11am CST in the United Imaging booth on Monday Dec 2. Pueblo Medical Imaging (PMI) has begun expanding to its sixth location in Nevada. The uMI Panvivo is part of its flagship location on South Rainbow Boulevard. PMI emphasizes easy access to state-of-the-art care for its growing patient community. "The addition of PET imaging marks a significant milestone in PMI's commitment to delivering the highest standard of care and we are extremely excited to step into the PET market with the best. Our mission has always been to provide our patients with the most advanced technology available, and partnering with United Imaging on the release of the Panvivo PET imaging system is a testament to that commitment," said Darren Blanford, CEO of Pueblo Medical Imaging. "The ability to detect cancer at earlier stages and offer more precise treatment options is a game-changer. By integrating this cutting-edge technology into our services, we can help our physicians make better-informed decisions, ultimately improving patient outcomes and quality of life." Wendy Winkle, the incoming Vice President of Molecular Imaging in the U.S., said that "the uMI Panvivo offers the same business innovations that come with the entire portfolio including Software Upgrades for Life™, providing all new software for the life of the system free of charge with an active service agreement , and All-in Configurations®, where every available application is included in the system configuration up front so it doesn't require a future purchase, helping to assure your business and patient care are optimized and standardized. We are excited to provide our partners at Pueblo Medical Imaging with innovative technology that serves their patients today and empowers the best care possible tomorrow and beyond." Jeffrey M. Bundy, PhD., CEO of United Imaging North America, expressed excitement about PMI's alignment with United Imaging's mission. "I am always so excited when our mission of Equal Healthcare for All™ aligns so well with our customers' own missions. PMI is about putting the most advanced care closer to their patients, so their patients don't have to travel as far or wait as long for top quality scans, and we could not be more proud to be part of PMI's present and future by installing this "first-in-the-world" scanner at their flagship location." At United Imaging, we develop and manufacture advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change. To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC. *Data on file.
SINGAPORE, Nov. 21, 2024 /PRNewswire/ -- Leading pulp, paper and board producer APRIL Group has further strengthened its commitment to improving public health by donating essential medical equipment to a local health facility in Riau province in Sumatra, Indonesia, close to where the company's manufacturing operations are located. APRIL, a member of the RGE group of companies, provided 22 types of essential medical equipment covering ultrasound machines, electrocardiogram (EKG) devices, infant warmers, laboratory tools and other healthcare instruments – worth more than IDR 300 million – to the Berkilau Health Centre in Pangkalan Kerinci. The donation was made through PT. Riau Andalan Pulp and Paper (PT. RAPP), the operating arm of APRIL Group. This contribution aims to enhance the quality and accessibility of healthcare services for the local communities and supports Indonesia's broader national health development goals. It is also aligned with the company's APRIL2030 strategy, which seeks to empower people and communities through transformative initiatives. Wan Mohammad Jakh Anza, General Manager of Stakeholder Relations, PT. RAPP, said: "Access to quality healthcare is a fundamental right of every individual. By providing medical equipment and collaborating with public health authorities, we aim to enhance primary healthcare and address critical issues like stunting". Dr. Diding Piliang, Head of the Berkilau Health Centre (the Centre), said the upgraded equipment have significantly enhanced the Centre's capacity in handling patients and reducing the need for hospital referrals. "Thanks to the support from APRIL, we can now provide better services, particularly in diagnostics and maternal health. For instance, procedures like pregnancy ultrasounds and heart diagnostics, which previously required hospital referrals, can now be completed here at the Centre," he said. Residents like Nurmay, a pregnant mother from Makmur Village, shared her positive experiences at the Centre. "With the new ultrasound device, the readings are more accurate which makes me feel more assured about my baby's health," she said. Beyond Berkilau Health Centre, APRIL has also distributed 300 medical devices to 10 other health centres across Pelalawan, including Pangkalan Kerinci 1 (Berseri), Pangkalan Kuras I and Bandar Petalangan. This initiative aligns with Pelalawan Regency Government's 2025 mission of improving human capital and infrastructure to strengthen regional economy. – Ends – About APRIL – www.aprilasia.com APRIL Group is a leading producer of fibre, pulp and paper with plantations and manufacturing operations in Riau Province, Indonesia. We are committed to sustainability in our business and in the broader landscapes where we operate. Under our production-protection model, we adopted a unique 1-for-1 goal where we aim to conserve one hectare of forest for every hectare of plantation, and currently conserve and restore about 360,000 hectares of forests, including the largest peatland restoration project in Indonesia. For more information, visit www.aprilasia.com and follow Twitter @aprilpulp.
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
